About River BioMedics

River BioMedics develops 3D in vitro human cardiac models, including a Heart-on-a-Chip and Mini-Heart, using human induced pluripotent stem cells for pre-clinical drug testing. This technology addresses the need for more predictive and clinically relevant platforms in cardiac drug discovery, enhancing the efficiency of therapeutic development for cardiovascular diseases.

```xml <problem> Traditional methods of pre-clinical cardiac drug testing often fail to accurately predict drug responses in humans, leading to costly late-stage failures in clinical trials. Existing 2D cell cultures and animal models do not fully replicate the complex 3D structure and function of the human heart, resulting in inaccurate assessments of drug efficacy and toxicity. </problem> <solution> River BioMedics develops advanced 3D in vitro human cardiac models utilizing human induced pluripotent stem cells (hiPSC) to provide more predictive and clinically relevant platforms for cardiac drug discovery. Their portfolio includes a 3D Cardiac Strip, Heart-on-a-Chip, and Mini-Heart, each designed to mimic the structure and function of the human heart muscle. These models enable researchers to directly target the heart muscle and obtain detailed, clinically relevant read-outs, enhancing the efficiency of therapeutic development for cardiovascular diseases. River BioMedics' technology aims to bridge the gap between pre-clinical testing and clinical outcomes, reducing the risk of late-stage drug failures. </solution> <features> - 3D Cardiac Strip: A multicellular cardiac tissue construct for evaluating contractile force and electrophysiological activity. - Heart-on-a-Chip: A microfluidic device that replicates the physiological microenvironment of the human heart, enabling real-time monitoring of cardiac function. - Mini-Heart: A miniaturized 3D cardiac model that mimics the structural and functional properties of the human heart, suitable for high-throughput screening. - hiPSC-derived cardiomyocytes: Models are created using human induced pluripotent stem cells, ensuring human-relevant cardiac tissue. - Clinically relevant read-outs: Provides detailed data on cardiac function, including contractility, electrophysiology, and calcium handling. - High-throughput screening: Enables efficient screening of drug candidates, accelerating the drug discovery process. </features> <target_audience> The primary customers are pharmaceutical companies, biotech firms, and academic research institutions involved in cardiac drug discovery and development. </target_audience> ```

What does River BioMedics do?

Where is River BioMedics located?

River BioMedics is based in Enschede, The Netherlands.

When was River BioMedics founded?

River BioMedics was founded in 2018.

How much funding has River BioMedics raised?

River BioMedics has raised 4250000.

Location

Enschede, The Netherlands

Founded

2018

Funding

4250000

Employees

16 employees

Major Investors

KIKK Capital, BioGeneration Ventures

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

River BioMedics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

riverbiomedics.com 1K+

Crunchbase

Founded 2018 – Enschede, The Netherlands

Funding

Estimated Funding

$3M+

Major Investors

KIKK Capital, BioGeneration Ventures

Team (15+)

No team information available.

Company Description

Problem

Traditional methods of pre-clinical cardiac drug testing often fail to accurately predict drug responses in humans, leading to costly late-stage failures in clinical trials. Existing 2D cell cultures and animal models do not fully replicate the complex 3D structure and function of the human heart, resulting in inaccurate assessments of drug efficacy and toxicity.

Solution

River BioMedics develops advanced 3D in vitro human cardiac models utilizing human induced pluripotent stem cells (hiPSC) to provide more predictive and clinically relevant platforms for cardiac drug discovery. Their portfolio includes a 3D Cardiac Strip, Heart-on-a-Chip, and Mini-Heart, each designed to mimic the structure and function of the human heart muscle. These models enable researchers to directly target the heart muscle and obtain detailed, clinically relevant read-outs, enhancing the efficiency of therapeutic development for cardiovascular diseases. River BioMedics' technology aims to bridge the gap between pre-clinical testing and clinical outcomes, reducing the risk of late-stage drug failures.

Features

3D Cardiac Strip: A multicellular cardiac tissue construct for evaluating contractile force and electrophysiological activity.

Heart-on-a-Chip: A microfluidic device that replicates the physiological microenvironment of the human heart, enabling real-time monitoring of cardiac function.

Mini-Heart: A miniaturized 3D cardiac model that mimics the structural and functional properties of the human heart, suitable for high-throughput screening.

hiPSC-derived cardiomyocytes: Models are created using human induced pluripotent stem cells, ensuring human-relevant cardiac tissue.

Clinically relevant read-outs: Provides detailed data on cardiac function, including contractility, electrophysiology, and calcium handling.

High-throughput screening: Enables efficient screening of drug candidates, accelerating the drug discovery process.

Target Audience

The primary customers are pharmaceutical companies, biotech firms, and academic research institutions involved in cardiac drug discovery and development.